Loading people...
Kevin Koch is the President, Chief Executive Officer, and Director of Edgewise Therapeutics, as well as a Venture Partner at OrbiMed. He previously co-founded Array BioPharma in 1998, serving as President and Chief Scientific Officer until 2013, where he built a research and development team responsible for inventing over twenty clinical candidates that resulted in several marketed medicines. Prior to his tenure at Array, Koch held the position of Senior Vice President of Drug Discovery at Biogen and served in senior scientific roles at both Amgen and Pfizer. He holds a doctorate in synthetic organic chemistry from the University of Rochester and has served as a Director at Skyhawk Therapeutics since 2018. His career spans over thirty years in the life sciences sector, with a primary focus on drug discovery, translational medicine, and the development of chemical therapeutics.
Kevin Koch is a distinguished Venture Partner at OrbiMed, one of the world's largest and most active healthcare-dedicated investment firms. In this pivotal role, he plays a crucial part in OrbiMed's mission to invest globally across the full spectrum of healthcare companies, from venture capital to public equities. As a Venture Partner, Kevin brings a wealth of experience and strategic insight to the firm's early-stage and growth equity investments, helping to identify and nurture the next generation of healthcare innovators.
Kevin's investment focus aligns with OrbiMed's broad mandate in the life sciences and healthcare sectors. This typically includes biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health. He is particularly interested in companies developing novel therapies, disruptive technologies, and innovative solutions that address significant unmet medical needs. His expertise helps OrbiMed identify promising ventures with strong scientific foundations and commercial potential, aiming to improve patient outcomes and advance medical science.
While specific details of Kevin Koch's full career trajectory are not publicly detailed in this profile, a Venture Partner at a firm like OrbiMed typically possesses a robust background combining scientific acumen, clinical understanding, and significant business development or operational experience within the healthcare industry. Such individuals often have a proven track record in drug development, medical technology, or healthcare management, enabling them to provide invaluable strategic guidance to portfolio companies. This deep industry knowledge is essential for evaluating complex scientific data, understanding market dynamics, and navigating regulatory landscapes.
As a Venture Partner, Kevin Koch contributes significantly to OrbiMed's extensive portfolio of healthcare investments. While specific individual investments directly attributed to him are not detailed in this profile, OrbiMed has a long history of backing transformative companies across various stages. Their portfolio includes numerous successful biotechnology firms, medical device innovators, and pharmaceutical companies that have brought important new treatments and technologies to market. Kevin's role involves collaborating with OrbiMed's investment teams to identify and support these high-potential ventures, contributing to the firm's overall success in shaping the future of healthcare. His involvement helps ensure that OrbiMed continues to invest in companies poised for significant impact and growth.
Kevin Koch is a Venture Partner at OrbiMed, a leading global healthcare investment firm. He specializes in identifying and supporting innovative companies within the life sciences sector.
Kevin Koch, through his role at OrbiMed, invests in a wide range of healthcare and life sciences companies. This includes biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health ventures that offer novel solutions and therapies.
Kevin Koch works as a Venture Partner at OrbiMed, a prominent healthcare-focused investment firm with a global presence.
